MedTrace Logo

The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure

NCT04810793 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 820

Last updated 2022-10-27

No results posted yet for this study

Summary

The patients who accepted the quadruple eradication program of the helicobacter pylori but failed to eradicate helicobacter pylori will be assessed the most suitable re-eradication time of helicobacter pylori.

Conditions

  • Helicobacter Pylori

Interventions

DRUG

Amoxicillin , Levofloxacin and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Levofloxacin-containing quadruple regimens

DRUG

Amoxicillin , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Amoxicillin-Furazolidone-containing quadruple regimens

DRUG

Tetracycline , Furazolidone and Esomeprazole

Esomeprazole-Bismuth-Tetracycline-Furazolidone-containing quadruple regimens

DRUG

Amoxicillin,Levofloxacin and Vonoprazan fumarate

Amoxicillin-Levofloxacin-Vonoprazan fumarate-containing quadruple group

DRUG

Amoxicillin,Furazolidone and Vonoprazan fumarate

Amoxicillin-Furazolidone-Vonoprazan fumarate-containing quadruple group

DRUG

Tetracycline,Furazolidone and Vonoprazan fumarate

Tetracycline-Furazolidone-Vonoprazan fumarate-containing quadruple group

Sponsors & Collaborators

  • Taian City Central Hospital

    collaborator OTHER

  • Dezhou People's Hospital

    collaborator OTHER

  • Weifang Medical University

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Shengli Oilfield Hospital

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Xiuli Zuo, MD,PhD · Qilu Hospital of Shandong University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-06-01
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810793 on ClinicalTrials.gov